Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 66Recruiting 65Completed 65Terminated 28Not yet recruiting 19Withdrawn 15Unknown 12Suspended 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 18Biopsy 16Cyclophosphamide 15Nivolumab 10Paclitaxel 9Vincristine 8Cisplatin 8venetoclax 7Prednisone 7Gemcitabine 7Doxorubicin 7Bevacizumab 7Azacitidine 7pembrolizumab 6Radiotherapy 6Fluorouracil 6Etoposide 6Drug Therapy 6Docetaxel 6Rituximab 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Injections 5Everolimus 5Capecitabine 5fludarabine phosphate 4Taxes 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Interventional × daratumumab × Clear all
NCT06348147 2026-05-04

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

UNC Lineberger Comprehensive Cancer Center

Phase 2 Suspended
39 enrolled
Plasma cell

Multiple Myeloma

NCT04661137 2026-02-10

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Hackensack Meridian Health

Phase 2 Suspended
96 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡